News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS), Shire Weighing $1.3 Billion Offer For ThromboGenics NV (TBGNF)



4/15/2014 8:02:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis AG (NOVN) and Shire Plc (SHP) are among drugmakers weighing offers for Belgian eye-medicine company ThromboGenics NV (THR), people familiar with the matter said. Novartis, which is based in Basel, Switzerland, is considered the most likely buyer because it already has a partnership to market ThromboGenics’s Jetrea eye medicine outside of the U.S., the people said, asking not to be identified because the process is private. The sale may value the company at as much as $1.3 billion, one of the people said.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES